CIPROFLOXACIN TABLETS, USP, 500 mg, 100 Tablets (10 tablets per blister card. 10 blister cards pe...

FDA Drug Recall #D-0377-2015 — Class II — September 26, 2013

Recall Summary

Recall Number D-0377-2015
Classification Class II — Moderate risk
Date Initiated September 26, 2013
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Location Rockford, IL
Product Type Drugs
Quantity 11,650 cartons

Product Description

CIPROFLOXACIN TABLETS, USP, 500 mg, 100 Tablets (10 tablets per blister card. 10 blister cards per carton), Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 51079-182-20.

Reason for Recall

CGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices

Distribution Pattern

Nationwide and Puerto Rico.

Lot / Code Information

Lot Number: 3034630; Expiration Date: 12/13; NDC: 51079-182-20

Other Recalls from Mylan Institutional, Inc. (d.b.a. UDL...

Recall # Classification Product Date
D-0861-2022 Class II Esomeprazole Magnesium Delayed-Release Capsules... Apr 1, 2022
D-0860-2022 Class II Esomeprazole Magnesium Delayed-Release Capsules... Apr 1, 2022
D-1013-2019 Class II Alprazolam Tablets, USP, 0.25 mg, 10x10 per car... Jan 18, 2019
D-1112-2018 Class III Diltiazem HCl Extended-release Capsules, USP 12... Aug 14, 2018
D-0822-2018 Class II Loxapine Capsules, USP 25 mg, packaged in 100 U... May 1, 2018

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.